Trials / Available
AvailableNCT06910137
An Early Access Program Guideline to Provide Access to Retifanlimab (INCMGA00012) Together With Carboplatin and Paclitaxel for Squamous Carcinoma of the Anal Canal (SCAC)
- Status
- Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
To provide retifanlimab, on a reactive basis, to adult patients with squamous carcinoma of the anal canal in combination with carboplatin and paclitaxel and who are considered ineligible for other therapeutic options including clinical trials.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | retifanlimab | Administered intravenous as defined in the protocol. |
Timeline
- First posted
- 2025-04-04
- Last updated
- 2026-01-08
Source: ClinicalTrials.gov record NCT06910137. Inclusion in this directory is not an endorsement.